Evaxion A/S
EVAX · XNASCIK 1828253fmd_048HDTYDBM8BK6KM40HGCF9HQ9Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Dec 31, 2025, 20 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 0 | 0 | 3 | 8 |
| Research and development | 4 | 8 | 11 | 20 | 17 | 12 | 10 | 10 |
| Operating income | (6) | (11) | (17) | (26) | (25) | (22) | (15) | (9) |
| Interest expense | 1 | 1 | 0 | 1 | 2 | 2 | 3 | 4 |
| Income before taxes | (6) | (12) | (17) | (25) | (24) | (23) | (11) | (9) |
| Income tax expense | (1) | (1) | (2) | (0) | (1) | (1) | (1) | (1) |
| Net income from continuing operations | (6) | (11) | (15) | (25) | (23) | (22) | (11) | (8) |
| Net income | (6) | (11) | (15) | (25) | (23) | (22) | (11) | (8) |
| Net income to common shareholders | (6) | (11) | (15) | (25) | (23) | (22) | – | – |